doi: 10.1016/s0264-410x(99)00399-0.
Primary respiratory syncytial virus infection: pathology, immune response, and evaluation of vaccine challenge strains in a new mouse model
Affiliations
- PMID: 10618539
- DOI: 10.1016/s0264-410x(99)00399-0
Item in Clipboard
Primary respiratory syncytial virus infection: pathology, immune response, and evaluation of vaccine challenge strains in a new mouse model
Vaccine.
.
Abstract
Respiratory syncytial virus (RSV) is the primary cause of lower respiratory tract illness in young children. Vaccine development has been hampered by the experience of the formalin-inactivated vaccine tested in the 1960's. Currently, several vaccine candidates are under development and immune response to these candidate vaccines must be evaluated closely. We introduce a novel low-dose murine model of RSV infection and a new pathologic scoring system for the resultant pulmonary disease. We have also developed new sensitive methods for measuring cytokine expression. We then used this new model to test vaccine challenge strains of RSV in order to determine their pathogenicity.
Similar articles
-
Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice.Vaccine. 2000 Nov 22;19(7-8):982-91. doi: 10.1016/s0264-410x(00)00213-9. Vaccine. 2000. PMID: 11115725
-
Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.Virology. 2000 Mar 30;269(1):54-65. doi: 10.1006/viro.2000.0186. Virology. 2000. PMID: 10725198
-
Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S46-57. doi: 10.1097/01.inf.0000108192.94692.d2. Pediatr Infect Dis J. 2004. PMID: 14730270 Review.
-
Cellular Immune Correlates Preventing Disease Against Respiratory Syncytial Virus by Vaccination with Virus-Like Nanoparticles Carrying Fusion Proteins.J Biomed Nanotechnol. 2017 Jan;13(1):84-98. doi: 10.1166/jbn.2017.2341. J Biomed Nanotechnol. 2017. PMID: 29302248 Free PMC article.
-
Pathogenesis of respiratory syncytial virus vaccine-augmented pathology.Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 2):S63-6. doi: 10.1164/ajrccm/152.4_Pt_2.S63. Am J Respir Crit Care Med. 1995. PMID: 7551416 Review.
Cited by
-
Induction of Interferon-Stimulated Genes Correlates with Reduced Growth of Influenza A Virus in Lungs after RIG-I Agonist Treatment of Ferrets.J Virol. 2022 Aug 24;96(16):e0055922. doi: 10.1128/jvi.00559-22. Epub 2022 Aug 2. J Virol. 2022. PMID: 35916513 Free PMC article.
-
Effects of cannabinoid receptor type 2 in respiratory syncytial virus infection in human subjects and mice.Virulence. 2018 Jan 1;9(1):217-230. doi: 10.1080/21505594.2017.1389369. Epub 2017 Dec 8. Virulence. 2018. PMID: 28992427 Free PMC article.
-
Impact and regulation of lambda interferon response in human metapneumovirus infection.J Virol. 2015 Jan;89(1):730-42. doi: 10.1128/JVI.02897-14. Epub 2014 Oct 29. J Virol. 2015. PMID: 25355870 Free PMC article.
-
Interleukin-12p40 modulates human metapneumovirus-induced pulmonary disease in an acute mouse model of infection.PLoS One. 2012;7(5):e37173. doi: 10.1371/journal.pone.0037173. Epub 2012 May 14. PLoS One. 2012. PMID: 22606349 Free PMC article.
-
The infectious march: the complex interaction between microbes and the immune system in asthma.Immunol Allergy Clin North Am. 2010 Nov;30(4):453-80, v. doi: 10.1016/j.iac.2010.09.008. Immunol Allergy Clin North Am. 2010. PMID: 21029932 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
